Churg-Strauss syndrome in an HCV seropositive patient.
Churg-Strauss syndrome was considered rare until leukotriene modifiers were introduced into medical practice in 1996. Since then, an increasing number of reports considering a possible relationship between leukotriene receptor antagonists and the Churg-Strauss syndrome have been published. Hepatitis C virus (HCV) is a blood-borne infection and a major health problem with an increasing prevalence worldwide. Previously, numerous reports suggested a relationship between HCV and certain autoimmune disorders such as cryoglobulinaemia and polyarteritis nodosa. We present a patient with HCV seropositive Churg-Strauss syndrome and a history of systemic corticosteroid and leukotriene receptor antagonist use, and discuss the possible risk factors in the aetiology of Churg-Strauss syndrome.
Dikensoy
O
O
Department of Pulmonary Diseases, Gaziantep University, School of Medicine, Gaziantep, Turkey.
Bayram
N G
NG
Erbagci
Z
Z
Namiduru
M
M
Filiz
A
A
Ekinci
E
E
D000328:Adult; D000420:Albuterol / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015153:Blotting, Western; D015267:Churg-Strauss Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D011282:Pregnenediones / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; C021988:deflazacort; D000420:Albuterol; D008775:Methylprednisolone